Why This Pharmaceutical Stock Jumped Almost 100% This Week
A mid-cap biotech surged close to 100% on news of a major deal and regulatory progress. This guide breaks down what h...
Using index funds to manage risk emphasizes broad diversification and low costs. These funds help smooth returns and reduce exposure to idiosyncratic losses.
27,240 articlesA mid-cap biotech surged close to 100% on news of a major deal and regulatory progress. This guide breaks down what h...
February brought an 11% slide in main street capital stock as investors weighed private credit risk and rising rates....
The (nrxp) 2026 earnings call highlights a shifting biotech landscape. This article breaks down what the results mean...
A Cytokinetics insider sale coincides with a stunning stock move. This article breaks down what the trade might signa...
When a founder dumps stock, investors naturally pause. This article explains what the Lindblad Expeditions sell after...
When prominent athletes face controversy, the financial implications go beyond contracts. This piece explores how Adr...
Two AI-focused names have pulled back recently, but their paths diverge. This guide breaks down why palantir sandisk ...
As allogene (allo) 2025 earnings loom, investors weigh pipeline progress, collaboration milestones, and cash runway. ...
As the Pentagon bets big on affordable, domestically produced drones, investors wonder if Red Cat Holdings can ride t...
Missed Sandisk's 580% rally? No worry. You can still ride the AI-driven chip surge with three smart stock picks, clea...
As markets wobble in early 2026, utility ETFs provide a steady dividend stream and a shield against volatility. This ...
A hantavirus outbreak unfolds, missing a coordinated federal response, leaving travelers and insurers scrambling for ...